{"entity":{"id":"invivoscribe","kind":"company","name":"Invivoscribe","aka":["Invivoscribe Technologies"],"tldr":"San Diego maker of blood cancer gene tests, including the FDA companion diagnostic for FLT3 inhibitors in acute myeloid leukaemia.","summary":"Invivoscribe, based in San Diego with offices in France and China and LabPMM clinical laboratories in the US, Germany and Japan, makes the LeukoStrat CDx FLT3 Mutation Assay, the FDA companion diagnostic for midostaurin, gilteritinib and quizartinib in acute myeloid leukaemia. Its other products are clonality and measurable residual disease tests for leukaemia and lymphoma.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://invivoscribe.com"},{"label":"FDA PMA P160040","url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P160040"}],"tags":[],"related":[],"cancers":["aml"],"sections":["diagnostics"],"technologies":["companion-diagnostic"],"targets":[],"drugs":["leukostrat-cdx-flt3"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"San Diego, CA","country":"US","companyType":"diagnostics","website":"https://invivoscribe.com","investors":[],"funding":[]},"route":"/companies/invivoscribe/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"}],"drug":[{"id":"leukostrat-cdx-flt3","kind":"drug","name":"LeukoStrat CDx FLT3 Mutation Assay","route":"/drugs/leukostrat-cdx-flt3/"}]}}